MX2009011744A - Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano. - Google Patents

Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano.

Info

Publication number
MX2009011744A
MX2009011744A MX2009011744A MX2009011744A MX2009011744A MX 2009011744 A MX2009011744 A MX 2009011744A MX 2009011744 A MX2009011744 A MX 2009011744A MX 2009011744 A MX2009011744 A MX 2009011744A MX 2009011744 A MX2009011744 A MX 2009011744A
Authority
MX
Mexico
Prior art keywords
methods
unit dose
treating
dose formulations
receptor antagonists
Prior art date
Application number
MX2009011744A
Other languages
English (en)
Inventor
David R Phillips
Gillian Stephens
Dacao Gao
Patrick Andre
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2009011744A publication Critical patent/MX2009011744A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona nuevos métodos para tratar trombosis y enfermedades cardiovasculares usando agentes antitrombóticos, así como métodos para determinar cantidades terapéuticamente efectivas de agentes antitrmobóticos y formulaciones de dosis unitaria de los mismos.
MX2009011744A 2007-05-03 2008-05-02 Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano. MX2009011744A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91578507P 2007-05-03 2007-05-03
US91578407P 2007-05-03 2007-05-03
US94731607P 2007-06-29 2007-06-29
US94728907P 2007-06-29 2007-06-29
PCT/US2008/062567 WO2008137793A1 (en) 2007-05-03 2008-05-02 Unit dose formulations and methods of treating and preventing thrombosis with thromboxane receptor antagonists

Publications (1)

Publication Number Publication Date
MX2009011744A true MX2009011744A (es) 2010-02-12

Family

ID=39943967

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2009011745A MX2009011745A (es) 2007-05-03 2008-05-02 Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras.
MX2009011744A MX2009011744A (es) 2007-05-03 2008-05-02 Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2009011745A MX2009011745A (es) 2007-05-03 2008-05-02 Uso de moduladores del receptor de tromboxano para el tratamiento de trastornos cardiovasculares en poblaciones sensibles a aspirina y otras.

Country Status (10)

Country Link
US (2) US20090012115A1 (es)
EP (2) EP2146573A4 (es)
JP (2) JP2010527331A (es)
KR (2) KR20100037029A (es)
CN (2) CN101686668A (es)
AU (2) AU2008247439A1 (es)
CA (2) CA2688317A1 (es)
IL (2) IL201885A0 (es)
MX (2) MX2009011745A (es)
WO (2) WO2008137791A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075028A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
AU2007344274A1 (en) * 2007-01-16 2008-07-24 Cardoz Ab New combination for use in the treatment of inflammatory disorders
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
AU2012336036A1 (en) * 2011-11-07 2014-06-19 Diakron Pharmaceuticals Inc. An extended release formulation of a direct thrombin inhibitor
JP6183459B2 (ja) * 2012-08-06 2017-08-23 Jnc株式会社 合成コラーゲンを用いる二重抗血小板薬／アスピリン応答および反応性試験
AU2015258805B2 (en) 2014-05-16 2018-05-10 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
AU2016285566A1 (en) * 2015-06-30 2017-12-14 Cumberland Pharmaceuticals, Inc. Thromboxane receptor antagonists in AERD/asthma
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895115A (en) * 1974-03-01 1975-07-15 Serono Ist Farm Method of inhibiting platelet aggregation
US5071866A (en) * 1989-07-31 1991-12-10 Bristol-Myers Squibb Company Arylpyrazole derivatives as anti-platelet agents
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
US5605917A (en) * 1994-12-22 1997-02-25 Bristol-Myers Squibb Company Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
WO2004004776A1 (en) * 2002-07-09 2004-01-15 B.M.R.A. Corporation B.V. Phamaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
WO2006066008A2 (en) * 2004-12-14 2006-06-22 Portola Pharmaceuticals, Inc. Device and methods for identifying and treating aspirin non-responsive patients
US7381536B2 (en) * 2005-03-01 2008-06-03 Gurbel Paul A Assessment of cardiac health and thrombotic risk in a patient

Also Published As

Publication number Publication date
EP2146573A4 (en) 2012-11-21
IL201886A0 (en) 2010-06-16
WO2008137791A1 (en) 2008-11-13
EP2146573A1 (en) 2010-01-27
JP2010527331A (ja) 2010-08-12
KR20100037029A (ko) 2010-04-08
CN101686668A (zh) 2010-03-31
KR20100032854A (ko) 2010-03-26
EP2144999A1 (en) 2010-01-20
CN101711279A (zh) 2010-05-19
MX2009011745A (es) 2010-02-12
IL201885A0 (en) 2011-08-01
JP2010526104A (ja) 2010-07-29
US20090012115A1 (en) 2009-01-08
US20090012136A1 (en) 2009-01-08
CA2688319A1 (en) 2008-11-13
WO2008137793A1 (en) 2008-11-13
EP2144999A4 (en) 2010-06-16
CA2688317A1 (en) 2008-11-13
AU2008247441A1 (en) 2008-11-13
AU2008247439A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
HRP20181459T1 (hr) Humanizirani antagonisti anti-beta7 i njihove uporabe
MX2009011744A (es) Formulaciones de dosis unitaria y metodos para tratar y prevenir trombosis con antagonistas del receptor de tromboxano.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
ME01532B (me) Jedinjenja
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
ATE469895T1 (de) Cgrp-rezeptorantagonisten
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
EA200970302A1 (ru) Тиофенпиразолопиримидиновые соединения
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA94737C2 (ru) Соединения на основе имидазола, композиция, которая их содержит, и их применение

Legal Events

Date Code Title Description
FA Abandonment or withdrawal